Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks*, Jill L. Ostrem, Leonard Verhagen, Philip A. Starr, Paul S. Larson, Roy AE Bakay, Robin Taylor, Deborah A. Cahn-Weiner, A. Jon Stoessl, C. Warren Olanow, Raymond T. Bartus
Dive into the research topics of 'Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial'. Together they form a unique fingerprint.